Bg pattern

SLENYTO 5 mg PROLONGED-RELEASE TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use SLENYTO 5 mg PROLONGED-RELEASE TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Slenyto 1 mg prolonged-release tablets

Slenyto 5 mg prolonged-release tablets

melatonin

Read all of this leaflet carefully before your child starts taking this medicine because it contains important information.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for your child, do not pass it on to others. It may harm them, even if their symptoms are the same as your child's.
  • If your child experiences any side effects, consult your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Slenyto and what is it used for
  2. What you need to know before you or your child starts taking Slenyto
  3. How to take Slenyto
  4. Possible side effects
  5. Storing Slenyto
  6. Contents of the pack and other information

1. What is Slenyto and what is it used for

What is Slenyto

Slenyto is a medicine that contains the active substance melatonin. Melatonin is a hormone that is naturally produced by the body.

What is Slenyto used for

Slenyto is used to treat insomnia (difficulty falling asleep) in:

  • children and adolescents(from 2 to 18 years of age) with autism spectrum disorder (ASD)and/or neurogenetic disorders(hereditary disorders that affect the nerves and brain) associated with abnormal melatonin levels and/or nighttime awakenings, if other healthy sleep routines (e.g., regular bedtime and relaxing sleep environment) have not worked well enough.
  • children and adolescents(from 6 to 17 years of age) with attention deficit hyperactivity disorder (ADHD), if other healthy sleep routines (e.g., regular bedtime and relaxing sleep environment) have not worked well enough.

Slenyto shortens the time it takes to fall asleep and prolongs the duration of sleep.

The medicine can help your child fall asleep and can help your child sleep longer during the night.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you or your child starts taking Slenyto

Do not take Slenyto if your child:

  • is allergic to melatonin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor or pharmacist before starting to take Slenyto if your child:

  • has liver or kidney problems. Consult your doctor before taking/administering Slenyto, as its use is not recommended in such cases.
  • has an autoimmune disease (where the body's immune system attacks parts of the body). Consult your doctor before taking/administering Slenyto, as its use is not recommended in such cases.

Slenyto can cause drowsiness and daytime fatigue. Caregivers should monitor the child for signs of daytime fatigue and seek advice from their doctor if symptoms appear.

In particular, children and adolescents with ADHD may experience an increase in daytime symptoms such as lack of attention, hyperactivity, or behavioral changes.

Children

The safety and efficacy of Slenyto in children under 6 years of age with ADHD have not been confirmed.

Do not give this medicine to children under 2 years of age, as its effects are unknown.

Other medicines and Slenyto

Tell your doctor or pharmacist if your child is taking, has recently taken, or might take any other medicines.

In particular, taking Slenyto with the following medicines may increase the risk of side effects or may affect how Slenyto or the other medicine works:

  • fluvoxamine(used to treat depression and obsessive-compulsive disorder)
  • methoxsalen(used to treat skin disorders such as psoriasis)
  • cimetidine(used to treat stomach problems such as ulcers)
  • quinolones(e.g., ciprofloxacin and norfloxacin) and rifampicin(used to treat bacterial infections)
  • estrogens(used in contraceptives or hormone replacement therapy)
  • carbamazepine(used to treat epilepsy)
  • non-steroidal anti-inflammatory drugssuch as acetylsalicylic acid and ibuprofen (used to treat pain and inflammation). These medicines should be avoided, especially at night.
  • beta blockers(used to control blood pressure). These medicines should be taken in the morning.
  • benzodiazepinesand non-benzodiazepine hypnoticssuch as zaleplon, zolpidem, and zopiclone (used to induce sleep)
  • thioridazine(used to treat schizophrenia)
  • imipramine(used to treat depression)

Tobacco

Tobacco can increase the breakdown of melatonin by the liver, which may make this medicine less effective. Inform your doctor if your child starts or stops smoking during treatment.

Taking Slenyto with alcohol

Do not drink alcohol before, during, or after taking Slenyto, as alcohol can weaken the effect of this medicine.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.

Tell your doctor or pharmacist before starting to take Slenyto if your child:

  • is pregnant or might be pregnant. As a precaution, it is preferable to avoid the use of melatonin during pregnancy.
    • is breastfeeding or plans to breastfeed. It is possible that melatonin may pass into human breast milk, so your doctor will decide whether you or your child should breastfeed while taking melatonin.

Driving and using machines

Slenyto can cause drowsiness. After taking this medicine, your child should not drive a vehicle, ride a bicycle, or use machines until they have fully recovered.

If your child experiences continuous drowsiness, they should consult their doctor.

Slenyto contains lactose

Slenyto contains lactose monohydrate. If your doctor has told your child that they have an intolerance to some sugars, consult them before taking this medicine.

3. How to take Slenyto

Follow exactly the administration instructions of this medicine given by your doctor.

In case of doubt, consult your doctor or pharmacist again.

Slenyto is available in two strengths: 1 mg and 5 mg.

Insomnia in children and adolescents (from 2 to 18 years of age) with ASD and/or neurogenetic disorders (hereditary disorders that affect the nerves and brain) associated with abnormal melatonin levels and/or nighttime awakenings.

The recommended initial dose is 2 mg (two 1 mg tablets) once a day. If your child's symptoms do not improve, your doctor may increase the dose of Slenyto to determine the most suitable dose for your child. The maximum daily dose that your child will receive is 10 mg (two 5 mg tablets).

Your doctor should regularly monitor your child (it is recommended every 6 months) to check that Slenyto is still the right treatment for your child.

Insomnia in children and adolescents (from 6 to 17 years of age) with ADHD

The recommended initial dose is 1-2 mg (one or two 1 mg tablets) once a day. If there is no improvement in your child's symptoms, the dose can be individually adjusted to 5 mg daily, regardless of age. If the doctor considers it necessary, the maximum daily dose can be increased to 10 mg (two 5 mg tablets) per day.

The lowest possible dose will be used for the shortest possible time.

Your doctor should regularly monitor your child (it is recommended every 6 months) to check that Slenyto is still the right treatment for your child.

The treatment should be interrupted once a year to check if it is still necessary.

When to take Slenyto

Slenyto should be taken at night, 30 to 60 minutes before bedtime. The tablets should be taken after dinner, i.e., with a full stomach.

How to take Slenyto

Slenyto is administered orally. The tablets should be swallowed whole, without being broken, crushed, or chewed. If the tablets are crushed or chewed, their special properties will be altered and they will not work correctly.

Whole tabletscan be introduced into foods such as yogurt, orange juice, or ice cream to help swallow them. If the tablets are mixed with these foods, they should be administered immediately and not left or stored, as this may affect how the tablets work. If the tablets are mixed with any other type of food, they may not work correctly.

If your child takes more Slenyto than they should

If your child has accidentally taken too much medicine, contact their doctor or pharmacist as soon as possible.

Taking more than the recommended daily dose may cause your child to feel drowsy.

If your child forgets to take Slenyto

If your child forgets to take a tablet, they can take it before bedtime that night, but after that time, no more tablets should be taken until the next night.

Do not take a double dose to make up for forgotten doses.

If your child stops taking Slenyto

Consult your doctor before your child stops taking Slenyto. It is important to continue taking this medicine to treat the disorder.

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Unpredictable changes in behavior, such as aggression (may affect up to 1 in 10 people), can occur frequently. If this change in behavior occurs, you should inform your doctor. It is possible that the doctor will want your child to stop taking this medicine.

If any of the following side effects become serious or troublesome, contact your doctor or seek medical attention:

Common: may affect up to 1 in 10 people

  • mood changes
  • aggression
  • irritability
  • drowsiness
  • headache
  • sudden sleepiness
  • swelling and inflammation of the breasts associated with pain and nasal congestion (sinusitis)
  • fatigue
  • hangover sensation

Frequency not known(reported from use in adults)

  • epilepsy
  • visual impairment
  • shortness of breath/difficulty breathing (dyspnea)
  • nosebleeds (epistaxis)
  • constipation
  • loss of appetite
  • facial swelling
  • skin injury
  • abnormal sensation
  • abnormal behavior
  • low white blood cell count (neutropenia)

Reporting of side effects

If your child experiences any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Slenyto

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month stated.

Do not store above 30 °C.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Package Contents and Additional Information

Slenyto Composition

Dose of 1 mg

  • The active ingredient is melatonin. Each tablet contains 1 mg of melatonin.
  • The other components are ammonio methacrylate copolymer type B, calcium hydrogen phosphate dihydrate, lactose monohydrate, colloidal anhydrous silica, talc, magnesium stearate, sodium carmellose (E466), maltodextrin, glucose monohydrate, lecithin (E322), titanium dioxide (E171), red iron oxide (E172), and yellow iron oxide (E172).

Dose of 5 mg

  • The active ingredient is melatonin. Each tablet contains 5 mg of melatonin.
  • The other components are ammonio methacrylate copolymer type A, calcium hydrogen phosphate dihydrate, lactose monohydrate, colloidal anhydrous silica, magnesium stearate, sodium carmellose (E466), maltodextrin, glucose monohydrate, lecithin (E322), titanium dioxide (E171), and yellow iron oxide (E172).

Product Appearance and Package Contents

Dose of 1 mg

Slenyto 1 mg prolonged-release tablets are film-coated, pink, round, biconvex, and 3 mm in diameter.

Available in blisters of 30/60 tablets.

Dose of 5 mg

Slenyto 5 mg prolonged-release tablets are film-coated, yellow, round, biconvex, and 3 mm in diameter.

Available in blisters of 30 tablets.

Only certain package sizes may be marketed.

Marketing Authorization Holder

RAD Neurim Pharmaceuticals EEC SARL

4 rue de Marivaux

75002 Paris

France

Email: [email protected]

Manufacturer

Iberfar - Indústria Farmacêutica, S.A.

Rua Consiglieri Pedrosa, n.° 121-123 Queluz de Baixo

Barcarena

2734-501

Portugal

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Belgium

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Lithuania

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Text in Bulgarian and contact details of RAD Neurim Pharmaceuticals EEC SARL including phone and email

Luxembourg

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Czech Republic

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Hungary

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Denmark

Takeda Pharma A/S

Tel: +45 46 77 11 11

Malta

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Germany

INFECTOPHARM Arzneimittel und Consilium GmbH

Tel: +49 6252 957000

Email: [email protected]

Netherlands

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Estonia

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Norway

Takeda AS

Tel: +47 6676 3030

Email: [email protected]

Greece

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Austria

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Spain

EXELTIS HEALTHCARE, S.L.

Tel: +34 91 7711500

Email: comunicació[email protected]

Poland

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

France

BIOCODEX

Tel: +33 (0)1 41 24 30 00

Email: [email protected]

Portugal

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Croatia

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Romania

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Ireland

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Slovenia

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Iceland

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Slovakia

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Italy

Fidia Farmaceutici S.p.A.

Tel: +39 049 8232355

Email: [email protected]

Finland

Biocodex Oy

Tel: +3589 329 59100

Email: [email protected]

Cyprus

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Sweden

Takeda Pharma AB

Tel: +46 8 731 28 00

Email: [email protected]

Latvia

RAD Neurim Pharmaceuticals EEC SARL

Tel: +33 185149776 (FR)

Email: [email protected]

Date of the Last Revision of this Leaflet: {month/YYYY}

Other Sources of Information

Detailed information about this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.

Online doctors for SLENYTO 5 mg PROLONGED-RELEASE TABLETS

Discuss questions about SLENYTO 5 mg PROLONGED-RELEASE TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (5)
Doctor

Anastasiia Hladkykh

Psychiatry 15 years exp.

Dr Anastasiia Hladkykh is a physician-psychotherapist and psychologist with over 14 years of experience working with individuals struggling with various types of addictions and their families. She provides online consultations for adults, combining medical knowledge with deep psychological support and practical tools.

Key areas of expertise:

  • Addiction treatment: alcohol and drug dependence, gambling addiction, compulsive behaviours, codependent relationships.
  • Support for families of addicted individuals, behavioural correction within the family system, guidance for maintaining remission.
  • Mental health: depression, bipolar disorder, obsessive-compulsive disorder (OCD), anxiety disorders, phobias, PTSD, generalised anxiety, emotional trauma, and the psychological impact of loss or emigration.
  • Psychoeducation: explaining complex mental health concepts in simple language, helping patients and their families understand diagnoses and treatment steps.
Therapeutic approach:
  • Client-centred, straightforward, and empathetic – focused on practical outcomes and emotional stabilisation.
  • Prescribes medications when needed, but always aims to minimise unnecessary pharmaceutical use.
  • Certified in multiple evidence-based methods: CBT, NLP (Master Practitioner), Ericksonian hypnosis, symbol drama, art therapy, and systemic therapy.
  • Each consultation results in a clear, structured plan – patients leave knowing exactly what to do next.
Experience and background:
  • Member of the German association Gesundheitpraktikerin and the NGO “Mit dem Sonne in jedem Herzen.”
  • More than 18 publications in international peer-reviewed journals, translated into several languages.
  • Volunteer work with Ukrainian refugees and military personnel at the University Clinic of Regensburg.
Camera Book a video appointment
€130
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for SLENYTO 5 mg PROLONGED-RELEASE TABLETS?
SLENYTO 5 mg PROLONGED-RELEASE TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in SLENYTO 5 mg PROLONGED-RELEASE TABLETS?
The active ingredient in SLENYTO 5 mg PROLONGED-RELEASE TABLETS is melatonin. This information helps identify medicines with the same composition but different brand names.
Who manufactures SLENYTO 5 mg PROLONGED-RELEASE TABLETS?
SLENYTO 5 mg PROLONGED-RELEASE TABLETS is manufactured by Rad Neurim Pharmaceuticals Eec S.A.R.L.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of SLENYTO 5 mg PROLONGED-RELEASE TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether SLENYTO 5 mg PROLONGED-RELEASE TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to SLENYTO 5 mg PROLONGED-RELEASE TABLETS?
Other medicines with the same active substance (melatonin) include CIRCADIN 2 mg PROLONGED-RELEASE TABLETS (30 tablets), CIRCADIN 2 mg PROLONGED-RELEASE TABLETS, MELATONIN ARROTEX 2 mg PROLONGED-RELEASE TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media